

Stefania Trazzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8437073/publications.pdf>

Version: 2024-02-01

32
papers

1,525
citations

304743

22
h-index

434195

31
g-index

39
all docs

39
docs citations

39
times ranked

1742
citing authors

#	ARTICLE	IF	CITATIONS
1	Age-Related Cognitive and Motor Decline in a Mouse Model of CDKL5 Deficiency Disorder is Associated with Increased Neuronal Senescence and Death. , 2021, 12, 764.		16
2	Treatment with a GSK-3 β /HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder. International Journal of Molecular Sciences, 2021, 22, 5950.	4.1	10
3	A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder. Neurobiology of Disease, 2021, 153, 105304.	4.4	9
4	Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder. Journal of Neuroinflammation, 2021, 18, 155.	7.2	21
5	Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder. Neuropharmacology, 2020, 167, 107746.	4.1	12
6	Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons. Molecular Neurobiology, 2020, 57, 2244-2262.	4.0	15
7	Functional and Structural Impairments in the Perirhinal Cortex of a Mouse Model of CDKL5 Deficiency Disorder Are Rescued by a TrkB Agonist. Frontiers in Cellular Neuroscience, 2019, 13, 169.	3.7	35
8	CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling. Brain Pathology, 2019, 29, 658-674.	4.1	17
9	CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder. Human Molecular Genetics, 2018, 27, 1572-1592.	2.9	49
10	Treatment with the GSK-3 β inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, <i>Cdkl5</i> knockout mice. European Journal of Neuroscience, 2018, 47, 1054-1066.	2.6	33
11	Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder. Neural Plasticity, 2018, 2018, 1-18.	2.2	39
12	HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. Human Molecular Genetics, 2016, 25, 3887-3907.	2.9	77
13	Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome. Neuroscience, 2016, 333, 277-301.	2.3	60
14	Inhibition of GSK3 β rescues hippocampal development and learning in a mouse model of CDKL5 disorder. Neurobiology of Disease, 2015, 82, 298-310.	4.4	55
15	Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease, 2015, 82, 385-396.	4.4	37
16	Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3 β signaling. Neurobiology of Disease, 2014, 70, 53-68.	4.4	105
17	APP-dependent alteration of GSK3 β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease, 2014, 67, 24-36.	4.4	33
18	Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome. Experimental Neurology, 2014, 251, 1-11.	4.1	18

#	ARTICLE	IF	CITATIONS
19	The Amyloid Precursor Protein (APP) Triplicated Gene Impairs Neuronal Precursor Differentiation and Neurite Development through Two Different Domains in the Ts65Dn Mouse Model for Down Syndrome. <i>Journal of Biological Chemistry</i> , 2013, 288, 20817-20829.	3.4	46
20	Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the <sc>Ts65Dn</sc> Mouse Model of <sc>D</sc>own Syndrome. <i>Brain Pathology</i> , 2013, 23, 129-143.	4.1	61
21	Early-occurring proliferation defects in peripheral tissues of the Ts65Dn mouse model of Down syndrome are associated with patched1 over expression. <i>Laboratory Investigation</i> , 2012, 92, 1648-1660.	3.7	21
22	CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2012, 1819, 1173-1185.	1.9	31
23	APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. <i>Human Molecular Genetics</i> , 2011, 20, 1560-1573.	2.9	106
24	Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome. <i>Journal of Neuroscience</i> , 2010, 30, 8769-8779.	3.6	164
25	CB1 Cannabinoid Receptors Increase Neuronal Precursor Proliferation through AKT/Glycogen Synthase Kinase-3 β / β -Catenin Signaling. <i>Journal of Biological Chemistry</i> , 2010, 285, 10098-10109.	3.4	73
26	The C-Terminal Domain of CENP-C Displays Multiple and Critical Functions for Mammalian Centromere Formation. <i>PLoS ONE</i> , 2009, 4, e5832.	2.5	50
27	Lot1 Is a Key Element of the Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)/Cyclic AMP Pathway That Negatively Regulates Neuronal Precursor Proliferation. <i>Journal of Biological Chemistry</i> , 2009, 284, 15325-15338.	3.4	18
28	DNMT3B interacts with constitutive centromere protein CENP-C to modulate DNA methylation and the histone code at centromeric regions. <i>Human Molecular Genetics</i> , 2009, 18, 3178-3193.	2.9	132
29	Functional cooperation between TrkA and p75NTR accelerates neuronal differentiation by increased transcription of GAP-43 and p21(CIP/WAF) genes via ERK1/2 and AP-1 activities. <i>Experimental Cell Research</i> , 2007, 313, 2980-2992.	2.6	28
30	In vivo functional dissection of human inner kinetochore protein CENP-C. <i>Journal of Structural Biology</i> , 2002, 140, 39-48.	2.8	32
31	CENP-C binds the alpha-satellite DNA in vivo at specific centromere domains. <i>Journal of Cell Science</i> , 2002, 115, 2317-2327.	2.0	67
32	CENP-C binds the alpha-satellite DNA in vivo at specific centromere domains. <i>Journal of Cell Science</i> , 2002, 115, 2317-27.	2.0	54